Jumjum Pharma Q3 profits reach 110.21 million

Jamjoom Pharmaceuticals Company's profits ("Jamjoom Pharma") increased by 3.32% year-on-year during the third quarter of 2026, reaching 110.21 million SAR compared to 106.67 million SAR in the same period last year. This growth is attributed to a 3.61% rise in revenues and an improved gross profit margin driven by manufacturing efficiency, product diversification, and geographic distribution of sales, despite higher operational expenses related to investments in growth initiatives. Additionally, the company recorded a 7.13% increase in revenues during the first nine months of the year and a 5.13% rise in net profits, along with a 10.58% increase in shareholders’ equity. On a quarterly basis, the company experienced a decline in both revenues and profits compared to the previous quarter.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل